McKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
McKesson Packaging Services is recalling Diltiazem HCl Extended-Release Capsules, 240 mg, because stability testing showed high dissolution results.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric associates with scores of 1 or 2. The hazard involves a failure to meet dissolution specifications, which is a quality defect rather than a direct safety hazard like contamination or mislabeling of a common allergen, fitting the 'Moderate' category for minor labeling or quality errors.
Plain-English summary
McKesson Packaging Services is recalling Diltiazem HCl Extended-Release Capsules, USP 240 mg, 100-count bottles. The recall involves 2,966 cartons of the medication, which was distributed nationwide in the United States. The specific lot number is 0115087, with an expiration date of 12/2018.
The recall was initiated because high dissolution results were obtained during stability testing, indicating that the product failed to meet dissolution specifications. This means the medication may not release the active ingredient at the intended rate.
Consumers and healthcare providers should check their inventory for this specific lot number and expiration date. If found, the product should be returned to the pharmacy or supplier for disposal or replacement. No specific instructions for patient management are provided in the source text.
The recalled product
- Product
- Diltiazem HCl Extended-Release Capsules, USP 240 mg, 100-count bottles, Rx Only, Mfg. By: Par Pharmaceutical One Ram Ridge Rd Chestnut Ridge, NY 10977. NDC: 63739-016-10
- Manufacturer
- Mckesson Packaging Services
- Category
- Drug — Cardiovascular
- Hazard
- Affected units
- 2,966
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 0115087
- Exp. 12/2018
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Mckesson Packaging Services under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Mckesson Packaging Services
See all →- LowMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateMcKesson Recalls Diltiazem CD Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateRanitidine Tablets Recalled for Failed Stability Specifications
FDA (Drugs) · 2018-03-14
- ModerateMcKesson Recalls Subpotent Megestrol Acetate Oral Suspension
FDA (Drugs) · 2018-02-14
- LowMcKesson Recalls Propafenone Hydrochloride Tablets for Moisture Content Issues
FDA (Drugs) · 2017-09-13
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17